标记物检测在妊娠中期唐氏综合征产前筛查中的价值分析

Objective To explore and analyze the value of serum marker testing in prenatal screening for down syndrome during the second trimester of pregnancy. Methods A total of 3,000 pregnant women who underwent secondtrimester down syndrome prenatal screening in the hospital from January 2023 to August 2025 were selected as the study subjects. Among them, 140 pregnant women with positive serum test results were designated as the observation group, while 2,860 pregnant women with negative serum test results served as the control group. Serum total β-human chorionic gonadotropin(β-HCG), alpha-fetoprotein(AFP), free estriol(uE3), and inhibin A(Inhibin-A) levels were measured for each group. The test results were comprehensively organized and analyzed. The pregnancy outcomes of the two groups were compared, along with their respective levels of β-HCG, AFP, uE3, and Inhibin-A. Results The observation group had a normal pregnancy outcome rate of 92.86%, while the control group showed a rate of 99.83%. The normal pregnancy outcome rate in the observation group was significantly lower than that in the control group(P<0.05). Additionally, the β-HCG and Inhibin-A levels in the observation group were higher than those in the control group, whereas the AFP and u E3 levels were lower in the observation group(P<0.05). Conclusion Implementing the four-marker screening protocol(β-HCG, AFP, uE3, Inhibin-A) during the second trimester can better predict fetal chromosomal trisomy conditions, assist healthcare providers in promptly identifying high-risk pregnant women, and provide efficient data support for the formulation of subsequent treatment plans.